RRP12

Across TCGA pan-cancer cohorts, RRP12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RRP12 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RRP12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RRP12 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, LUSC, and SKCM are the cancer types where RRP12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	24	view →
LUSC	DFS	Median	III,IV	0.010	0.754	<.001	19	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	19	view →
UCEC	DFS	Median	All	0.969	0.621	.004	12	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RRP12–ACC (DFS)

Open the ACC breakdown →